NEW YORK, Feb. 27, 2018 -- Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to reach $2.96 billion by 2024 Says, Profshare Market Research; growing at a CAGR of 6.6% between 2016 and 2024.If the constipation happens chronically with an unidentifiable cause it is known as Chronic Idiopathic Constipation (CIC). The word “Idiopathic” means the cause is not known. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.
Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs. After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome. Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.
Get Free Sample: https://www.profsharemarketresearch.com/sample/chronic-idiopathic-constipation-cic-drugs-market-sample/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: End Users/Application Analysis
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Product Type
- Lubiprostone
- Linaclotide
Report Enquiry: https://www.profsharemarketresearch.com/enquiry/chronic-idiopathic-constipation-cic-drugs-market-enquiry/
Global Chronic Idiopathic Constipation (CIC) Drugs Market: Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Chronic Idiopathic Constipation (CIC) Drugs:
- Actavis
- Chugai Pharmaceutical
- Ferring International Center S.A.
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding AG
- Sanofi
- Bayer AG
- Salix Pharmaceuticals Ltd
- Sucampo Pharmaceuticals Inc
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Buy Report: https://www.profsharemarketresearch.com/buy/chronic-idiopathic-constipation-cic-drugs-market-buy-su/
Contact Us:
Mia Cox,
Email- [email protected]
Tel- 1-877-797-7295
www.profsharemarketresearch.com


ByteDance Secures $29.6 Billion Loan to Boost AI Investment
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies
Shein Shares Drop 5% After Weak Hong Kong IPO Debut
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability
Anthropic Nears $15 Billion Credit Deal Ahead of IPO
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall
Lynas Rare Earths Shares Rise After Takeover Talks Revealed
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities
Milei Threatens Falkland Oil Firms With Sanctions
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 



